Login / Signup

Antiosteoporosis therapy after discontinuation of menopausal hormone therapy: a systematic review.

Panagiotis AnagnostisEfstathios DivarisJulia Κ BosdouSymeon TournisKonstantinos StathopoulosDimitrios G Goulis
Published in: Hormones (Athens, Greece) (2024)
Antiresorptive therapy with either a bisphosphonate (i.e., alendronate) or raloxifene could be considered a sequential antiosteoporosis therapy after MHT withdrawal since they have been shown in studies to further increase BMD. However, no safe conclusions can be drawn from the existing literature.
Keyphrases
  • systematic review
  • stem cells
  • bone marrow
  • cell therapy
  • smoking cessation